All In Biotech

Drug Trial Radar · NCT04672525

Rifabutin Versus Rifampicin for Treatment of Staphylococcal PJI Treated With DAIR

Rifabutin Versus Rifampicin for Treatment of Staphylococcal Prosthetic Joint Infection Treated With Debridement, Antibiotics and Implant Retention (DAIR Strategy): a Multicenter Randomized, Open-label, Non-inferiority Trial

Last checked: Nov 19, 2026Latest source record: May 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 436 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

436

Planned (sponsor's estimate)

Start

Nov 8, 2021

Primary completion

Nov 2026

Study completion Jun 2027

Sponsor

Lead sponsor
Tourcoing HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 17, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Rifampicin, is key in the treatment of staphylococcal PJIs. Rifabutin has a better profile of tolerance than rifampicin regarding the risk of interaction with concomitant medications and liver disorders. The hypothesis is that rifabutin may be an alternative antibiotic option as efficient as rifampicin for the treatment of staphylococcal PJIs, with a better safety profile. The investigator aim to demonstrate the non-inferiority of rifabutin as compared with rifampicin prescribed in combination treatment for PJIs.

Conditions

  • Prosthetic Infection

Interventions

  • RifabutinDrug

    2 tablets of 150 mg per day rifabutin tablet daily for 12 weeks in 1 administration with a companion treatment

  • RifampicinDrug

    10 mg/kg per day (range 600 mg to 1,200 mg) rifampicin tablet in 1 daily dose for 12 weeks with a companion treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment failureTime frame: At one year

Locations

30 sites in 1 country. Site status is shown where the registry gives one.

  • CHU Amiens Picardie

    Amiens, France · Not yet recruiting

  • CHU Angers

    Angers, France · Not yet recruiting

  • CHU Besançon

    Besançon, France · Recruiting

  • CH de Béthune

    Béthune, France · Not yet recruiting

  • CHU Bordeaux

    Bordeaux, France · Not yet recruiting

  • APHP Hôpital Ambroise Paré

    Boulogne-Billancourt, France · Not yet recruiting

  • CHRU Brest

    Brest, France · Recruiting

  • CHU Caen

    Caen, France · Recruiting

  • CH Alpes Leman

    Contamine-sur-Arve, France · Not yet recruiting

  • CHU Dijon Bourgogne

    Dijon, France · Not yet recruiting

  • CHU Grenoble Alpes

    Grenoble, France · Not yet recruiting

  • CHRU Lille

    Lille, France · Recruiting

  • GHICL Hôpital Saint Vincent de Paul

    Lille, France · Not yet recruiting

  • CHU de Limoges

    Limoges, France · Recruiting

  • GHICL Hôpital Saint Philibert

    Lomme, France · Not yet recruiting

  • Clinique de la Sauvegarde

    Lyon, France · Not yet recruiting

  • Hospices Civils de Lyon

    Lyon, France · Not yet recruiting

  • APHM Hôpital Nord

    Marseille, France · Not yet recruiting

  • CHU Nice

    Nice, France · Not yet recruiting

  • CH Annecy Genevois

    Pringy, France · Recruiting

  • CH Cornouaille

    Quimper, France · Not yet recruiting

  • CHU Reims

    Reims, France · Not yet recruiting

  • CHU de Rennes

    Rennes, France · Recruiting

  • CHU Saint Etienne

    Saint-Priest-en-Jarez, France · Not yet recruiting

  • CHRU Strasbourg

    Strasbourg, France · Not yet recruiting

  • Hôpital d'instruction des armées Sainte Anne

    Toulon, France · Recruiting

  • Clinique Joseph Ducuing

    Toulouse, France · Not yet recruiting

  • Clinique Médipole Garonne

    Toulouse, France · Not yet recruiting

  • CH Tourcoing

    Tourcoing, France · Recruiting

  • CHRU Tours

    Tours, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.